TVB 2640

Drug Profile

TVB 2640

Alternative Names: TVB-2640

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator 3-V Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Phase Unknown Colorectal cancer

Most Recent Events

  • 29 Nov 2016 University of Kentucky plans a phase I trial for Colon cancer (Resectable) in USA (PO) (NCT02980029)
  • 12 Oct 2016 Investigation in Colorectal cancer in USA (PO)
  • 01 Oct 2016 3-V Biosciences plans a phase I/II trial for Metabolic syndrome in USA (NCT02948569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top